Results 51 to 60 of about 19,649 (222)

Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction [PDF]

Blood, 1989
The Philadelphia (Ph′) chromosome in chronic myelogenous leukemia (CML) results in fusion of the bcr gene and c-abl oncogene, which transcribes into two types of chimeric bcr/abl mRNAs: the L-6 junction and the K-28 junction. By means of a highly sensitive assay, combination of reverse transcription and polymerase chain reaction (RT/PCR), we analyzed ...
M S, Lee, A, LeMaistre, H M, Kantarjian, M, Talpaz, E J, Freireich, J M, Trujillo, S A, Stass   +6 more
openaire   +3 more sources

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Hatziieremia, S., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Mountford, J.C.   +4 more
core   +1 more source

Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors

Iraqi Journal of Hematology, 2020
BACKGROUND: Chronic myelogenous leukemia (CML) is a hematological stem cell disorder that associates with mutations in BCR-ABL. Although mutations identified in more than 30 different amino acids, the highest degree of resistance was associated with ...
Riyam Qusay Ibrahim Al-Jadir, Jaffar Nouri Alalsaidissa   +1 more
doaj   +1 more source

Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy [PDF]

Vojnosanitetski Pregled, 2012
Background/Aim. Introducing tyrosine kinase inhibitors (TKIs) has essentially changed curative approach, to be precise, clearly improved treatment efficacy for chronic myeloid leukemia (CML).
Stamatović Dragana, Balint Bela, Tukić Ljiljana, Elez Marija, Tarabar Olivera, Todorović Milena, Todorić-Živanović Biljana, Ostojić Gordana, Tatomirović Željka, Marjanović Slobodan, Malešević Milomir   +10 more
doaj   +1 more source

Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML [PDF]

, 1991
Between 1985 and 1989, many cases of Philadelphia (Ph) chromosome negative chronic myelogenous leukemia (CML) were reported. For this review, the following selection criteria were used: the original articles on Ph-negative cases should provide clinical ...
Grosveld, G.C. (Gerard), Hagemeijer, A. (Anne), Plas, D. (D.) van der   +2 more
core   +1 more source

Interferon-alpha-Treated Patients with Chronic Myelogenous Leukemia Show BCR/ABL-Positive Peripheral Blood Progenitor Cells Surviving Long-Term Culture

Folia Biologica, 2000
Several groups have shown that Ph-progenitors reappear in LTC of CML bone marrow or PBMNC when the cell preparations were derived from newly diagnosed Ph-positive patients or after induction chemotherapy. We have tested the hypothesis whether LTC may further decrease CML progenitors if the cells to be cultured were from IFN-treated
B, Schultheis, B, Heissig, G, Pasternak, S, Hörner, R, Hehlmann   +4 more
openaire   +2 more sources

Chronic myeloid leukemia-clinical, experimental and health economic studies with special reference to imatinib treatment [PDF]

, 2013
CML is a malignant disease that originates in the bone marrow stem cell, carrying the Philadelphia chromosome with the BCR-ABL fusion gene. This gene translates into an active tyrosine kinase, Bcr-Abl, affecting hematopoiesis, particularly resulting in ...
Ohm, Lotta
core   +1 more source

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells [PDF]

, 2011
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease ...
A Quintas-Cardama, A Quintas-Cardama, A Quintas-Cardama, AJ Tipping, AJ Tipping, B Zhang, C Akgul, C Bellodi, G Gurel, H de Lavallade, H Konig, HG Jorgensen, HM Kantarjian, J Kuroda, KJ Aichberger, L Legros, M Copland, M Copland, NB Heaney, R Chen, R Tang, RG Powell, RM Stone, S Chu, SM Graham, SV Sharma, T Kobayashi, Y Chen   +27 more
core   +1 more source

Is There an Entity of Chemically Induced BCR-ABL–Positive Chronic Myelogenous Leukemia?

The Oncologist, 2008
Abstract Learning Objectives After completing this course, the reader will be able to: Distinguish the exogenous causes of acute and chronic myelogenous leukemia.Discuss the evidence establishing the exogenous causes of secondary leukemia.Describe the relationship of radiation and chemical exposure to
openaire   +2 more sources

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source